Prospective trial of treat-and-extend versus monthly dosing for neovascular age-related macular degeneration: TREX-AMD 1-year results

Keyphrases

• Age-related Macular Degeneration 100%
• Neovascular Age-related Macular Degeneration (nAMD) 100%
• Monthly Dosing 100%
• Treat-and-extend 100%
• Best-corrected Visual Acuity 40%
• Management Strategy 20%
• Exudative 20%
• Disease Activity 20%
• Nave 20%
• Early Treatment Diabetic Retinopathy Study 20%
• Anatomic 10%
• Retinal Thickness 10%
• Intravitreal 10%
• Multicenter Randomized Controlled Trial 10%
• Change from Baseline 10%
• Randomized Controlled Clinical Trial 10%
• Number of Injections 10%
• Intravitreal Ranibizumab 10%
• Ranibizumab 10%
• Spectral Domain Optical Coherence Tomography (SD-OCT) 10%
• Clinical Domain 10%
• Design Phase 10%
• Visual Acuity Change 10%
• Treat-and-extend Protocol 10%

Medicine and Dentistry

• Age Related Macular Degeneration 100%
• Best Corrected Visual Acuity 100%
• Wet Macular Degeneration 100%
• Diabetic Retinopathy 50%
• Disease Activity 50%
• Ranibizumab 50%
• Randomized Controlled Trial 25%
• Controlled Clinical Trial 25%
• Spectral Domain Optical Coherence Tomography 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Age Related Macular Degeneration 100%
• Wet Macular Degeneration 100%
• Disease Activity 50%
• Ranibizumab 50%
• Diabetic Retinopathy 50%
• Controlled Clinical Trial 25%
• Randomized Controlled Trial 25%